12399456https://www.upal.com.my/zh/feeds/jobFeedKwongwahArray ( [0] => HTTP/1.1 200 OK [1] => Date: Wed, 27 May 2026 06:26:37 GMT [2] => Content-Type: text/xml; charset=utf-8 [3] => Connection: close [4] => Cache-Control: no-cache, private [5] => Cache-Control: no-cache, no-store, must-revalidate [6] => Set-Cookie: UpalLiveSession=eyJpdiI6IlF3S3M3dEdNZ0x4TEFZYlhMSm84clE9PSIsInZhbHVlIjoiUXdSb0RSdDhTTHFHWDVnNjdFamhqQzU1TEVvMjZpbUl3MlcxY2kyaGdKcTBMT1krN3d3N1V2U2phUTVtc0FSUlJBd0ZIYlZrbEp2OEFHRTRCVlo5UkE9PSIsIm1hYyI6ImRmODNiYjhlODA4ZTJlMTE4ZmU4MjM0ZTU0YWEwMzA1NGM1NDI2ODgxYjRiNmJiNzk1MDdjNWIwMjE2YmEwZjYifQ%3D%3D; expires=Sat, 26-May-2029 06:26:37 GMT; Max-Age=94608000; path=/; HttpOnly [7] => x-frame-options: SAMEORIGIN [8] => x-content-type-options: nosniff [9] => x-xss-protection: 1; mode=block [10] => referrer-policy: strict-origin-when-cross-origin [11] => permissions-policy: geolocation=(), microphone=(), camera=() [12] => content-security-policy: default-src * 'unsafe-inline' 'unsafe-eval' data: blob:; script-src * 'unsafe-inline' 'unsafe-eval' data: blob:; style-src * 'unsafe-inline' data:; img-src * data: blob:; font-src * data:; connect-src *; frame-src *; object-src *; media-src *; child-src *; [13] => Server: cloudflare [14] => x-robots-tag: noindex, nofollow, nosnippet, noarchive [15] => strict-transport-security: max-age=31536000; includeSubDomains; preload [16] => expires: Thu, 28 May 2026 06:26:37 GMT [17] => vary: Accept-Encoding [18] => Report-To: {"group":"cf-nel","max_age":604800,"endpoints":[{"url":"https://a.nel.cloudflare.com/report/v4?s=K%2FIK7wc%2BCb%2FfpSeTTUwIh6BJd88NVcFPZIRb%2Bxa%2FN6hO5BjotJtmh269%2BxhwY5vS51phvLh9Fj7x803fjRamZ%2B3SqyMEeHDSbc%2F%2FZfmS5PPriwnpJ8H5B1nXaJYpC44eQCc%3D"}]} [19] => cf-cache-status: DYNAMIC [20] => Nel: {"report_to":"cf-nel","success_fraction":0.0,"max_age":604800} [21] => Speculation-Rules: "/cdn-cgi/speculation" [22] => Server-Timing: cfCacheStatus;desc="DYNAMIC" [23] => Server-Timing: cfEdge;dur=7,cfOrigin;dur=742 [24] => CF-RAY: a022f2f4082ff7e3-LAX [25] => alt-svc: h3=":443"; ma=86400 ) 789

由中国广东省内专家研制、针对新冠肺炎的中成药“肺炎一号”，于周四正式委托药厂量产，药厂预料下周可以陆续出货，供应予省内各医院使用。但该款新药属于医院制剂，根据规定，它只能在已申报的医院内部使用，一般市民暂时无法购买。

据当地媒体报道，该款新药由5味药材制成，配方并未公开，在周二已获得省药品监督管理局优先审批通过，由广东一方制药有限公司生产。按目前公布的资料，该药有效期为半年，仅对轻症患者有治疗功效，并无预防作用，非确诊者毋须服用。，

省药品监管局早前曾进行临床试验，供广州市第八人民医院的50名轻症患者临床服用该款新药，结果50%患者的咳嗽症状消失、52.4%的咽痛症状消失、69.6%的乏力症状消失，整体症状明显好转，具较好的临床价值。

---

// // // //